{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:32:39Z","timestamp":1792801959379,"version":"4.5.0"},"reference-count":35,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"24","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2000,12,15]]},"abstract":"<jats:p> PURPOSE: This study investigated the prognostic value of quantifying tumor cells in bone marrow and blood by immunocytology in children with high-risk, metastatic neuroblastoma. <\/jats:p><jats:p> PATIENTS AND METHODS: Patients with stage IV neuroblastoma (N = 466) registered on Children\u2019s Cancer Group study 3891 received five cycles of induction chemotherapy and were randomized either to myeloablative chemoradiotherapy with autologous purged bone marrow rescue or to nonmyeloablative chemotherapy. Subsequently, they were randomized to 13-cis-retinoic acid or no further treatment. Immunocytologic analyses of bone marrow and blood were performed at diagnosis, week 4, week 12, bone marrow collection, and end induction and were correlated with tumor biology, clinical variables, treatment regimen, and event-free survival (EFS). <\/jats:p><jats:p> RESULTS: Immunocytology identified neuroblastoma cells in bone marrow of 81% at diagnosis, 55% at 4 weeks, 27% at 12 weeks, 19% at bone marrow collection, and 14% at end induction. Tumor cells were detected in blood of 58% at diagnosis and 5% at collection. There was an adverse effect on EFS of increasing tumor cell concentration in bone marrow at diagnosis (P = .04), at 12 weeks (P = .006), at bone marrow collection (P &lt; .001), and at end induction (P = .07). Positive blood immunocytology at diagnosis was associated with decreased EFS (P = .003). The prognostic impact of immunocytology was independent of morphologically detected bone marrow disease, MYCN status, and serum ferritin level in bivariate Cox analyses. <\/jats:p><jats:p> CONCLUSION: Immunocytologic quantification of neuroblastoma cells in bone marrow and blood at diagnosis and in bone marrow during induction chemotherapy provides prognostic information that can identify patients with very high-risk disease who should be considered for experimental therapy that might improve outcome. <\/jats:p>","DOI":"10.1200\/jco.2000.18.24.4067","type":"journal-article","created":{"date-parts":[[2017,2,24]],"date-time":"2017-02-24T06:42:41Z","timestamp":1487918561000},"page":"4067-4076","source":"Crossref","is-referenced-by-count":142,"title":["Quantitative Tumor Cell Content of Bone Marrow and Blood as a Predictor of Outcome in Stage IV Neuroblastoma: A Children\u2019s Cancer Group Study"],"prefix":"10.1200","volume":"18","author":[{"given":"Robert C.","family":"Seeger","sequence":"first","affiliation":[{"name":"From the Departments of Pediatrics and Pathology, University of Southern California School of Medicine and Childrens Hospital; and Department of Preventive Medicine, University of Southern California School of Medicine, Los Angeles; Children\u2019s Cancer Group, Arcadia; and Department of Pediatrics, University of California School of Medicine, San Francisco, CA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Patrick","family":"Reynolds","sequence":"additional","affiliation":[{"name":"From the Departments of Pediatrics and Pathology, University of Southern California School of Medicine and Childrens Hospital; and Department of Preventive Medicine, University of Southern California School of Medicine, Los Angeles; Children\u2019s Cancer Group, Arcadia; and Department of Pediatrics, University of California School of Medicine, San Francisco, CA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Gallego","sequence":"additional","affiliation":[{"name":"From the Departments of Pediatrics and Pathology, University of Southern California School of Medicine and Childrens Hospital; and Department of Preventive Medicine, University of Southern California School of Medicine, Los Angeles; Children\u2019s Cancer Group, Arcadia; and Department of Pediatrics, University of California School of Medicine, San Francisco, CA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel O.","family":"Stram","sequence":"additional","affiliation":[{"name":"From the Departments of Pediatrics and Pathology, University of Southern California School of Medicine and Childrens Hospital; and Department of Preventive Medicine, University of Southern California School of Medicine, Los Angeles; Children\u2019s Cancer Group, Arcadia; and Department of Pediatrics, University of California School of Medicine, San Francisco, CA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert B.","family":"Gerbing","sequence":"additional","affiliation":[{"name":"From the Departments of Pediatrics and Pathology, University of Southern California School of Medicine and Childrens Hospital; and Department of Preventive Medicine, University of Southern California School of Medicine, Los Angeles; Children\u2019s Cancer Group, Arcadia; and Department of Pediatrics, University of California School of Medicine, San Francisco, CA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine K.","family":"Matthay","sequence":"additional","affiliation":[{"name":"From the Departments of Pediatrics and Pathology, University of Southern California School of Medicine and Childrens Hospital; and Department of Preventive Medicine, University of Southern California School of Medicine, Los Angeles; Children\u2019s Cancer Group, Arcadia; and Department of Pediatrics, University of California School of Medicine, San Francisco, CA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"R1-0558","doi-asserted-by":"publisher","DOI":"10.1097\/00043426-199905000-00005"},{"key":"R2-0558","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199101243240403"},{"key":"R3-0558","doi-asserted-by":"publisher","DOI":"10.1089\/hyb.1985.4.289"},{"key":"R4-0558","unstructured":"Cheung  NK,   Saarinen  UM,   Neely  JE,  et al:  Monoclonal antibodies to a glycolipid antigen on human neuroblastoma cells.   Cancer Res 45:  2642,1985-2649,"},{"key":"R5-0558","doi-asserted-by":"publisher","DOI":"10.1089\/hyb.1986.5.297"},{"key":"R6-0558","doi-asserted-by":"publisher","DOI":"10.3109\/08880018909034273"},{"key":"R7-0558","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1988.tb02404.x"},{"key":"R8-0558","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.44.6.483"},{"key":"R9-0558","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.44.4.309"},{"key":"R10-0558","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19941101)74:9<2403::AID-CNCR2820740904>3.0.CO;2-F"},{"key":"R11-0558","doi-asserted-by":"crossref","unstructured":"Nagai  J,   Kigasawa  H,   Tomioka  K,  et al:  Immunocytochemical detection of bone marrow-invasive neuroblastoma cells.   Eur J Haematol 53:  74,1994-77,","DOI":"10.1111\/j.1600-0609.1994.tb01868.x"},{"key":"R12-0558","unstructured":"Matthay  KK,   Reynolds  CP,   Stram  DO,  et al:  Quantitative tumor cell content of bone marrow and blood as an early predictor of response in high risk neuroblastoma:   A Children\u2019s Cancer Group study.   Proc Am Soc Clin Oncol 16:  512a,1997  (abstr 1844)"},{"key":"R13-0558","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.8.2807"},{"key":"R14-0558","doi-asserted-by":"publisher","DOI":"10.1097\/00043426-199807000-00003"},{"key":"R15-0558","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199910143411601"},{"key":"R16-0558","unstructured":"Hann  HW,   Evans  AE,   Siegel  SE,  et al:  Prognostic importance of serum ferritin in patients with Stages III and IV neuroblastoma:   The Childrens Cancer Study Group experience.   Cancer Res 45:  2843,1985-2848,"},{"key":"R17-0558","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198510313131802"},{"key":"R18-0558","unstructured":"Seeger  RC,   Wada  R,   Brodeur  GM,  et al:  Expression of N-myc by neuroblastomas with one or multiple copies of the oncogene.   Prog Clin Biol Res 271:  41,1988-49,"},{"key":"R19-0558","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/73.2.405"},{"key":"R20-0558","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1993.11.8.1466"},{"key":"R21-0558","doi-asserted-by":"publisher","DOI":"10.1016\/S0031-3955(16)38084-1"},{"key":"R22-0558","unstructured":"Reynolds  CP,   Seeger  RC,   Vo  DD,  et al:  Model system for removing neuroblastoma cells from bone marrow using monoclonal antibodies and magnetic immunobeads.   Cancer Res 46:  5882,1986-5886,"},{"key":"R23-0558","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1994.12.11.2382"},{"key":"R24-0558","doi-asserted-by":"publisher","DOI":"10.1080\/01621459.1958.10501452"},{"key":"R25-0558","doi-asserted-by":"publisher","DOI":"10.1016\/0010-4809(77)90006-4"},{"key":"R26-0558","doi-asserted-by":"crossref","unstructured":"Cox  DR:   Regression models and life tables.   J R Stat Soc 34:  187,1972-220,","DOI":"10.1111\/j.2517-6161.1972.tb00899.x"},{"key":"R27-0558","unstructured":"Reynolds  CP,   Kane  DJ,   Einhorn  PA,  et al:  Response of neuroblastoma to retinoic acid in vitro and in vivo.   Prog Clin Biol Res 366:  203,1991-211,"},{"key":"R28-0558","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19971101)80:9<1717::AID-CNCR4>3.0.CO;2-B"},{"key":"R29-0558","unstructured":"Mattano  LA Jr,   Moss  TJ,   Emerson  SG:   Sensitive detection of rare circulating neuroblastoma cells by the reverse transcriptase-polymerase chain reaction.   Cancer Res 52:  4701,1992-4705,"},{"key":"R30-0558","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V83.10.3085.3085"},{"key":"R31-0558","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19910301)67:5<1423::AID-CNCR2820670525>3.0.CO;2-L"},{"key":"R32-0558","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19980201)82:3<591::AID-CNCR23>3.0.CO;2-W"},{"key":"R33-0558","doi-asserted-by":"publisher","DOI":"10.1620\/tjem.184.229"},{"key":"R34-0558","doi-asserted-by":"crossref","unstructured":"Burchill  SA,   Bradbury  FM,   Selby  P,  et al:  Early clinical evaluation of neuroblastoma cell detection by reverse transcriptase-polymerase chain reaction (RT-PCR) for tyrosine hydroxylase mRNA.   Eur J Cancer 31A:  553,1995-556,","DOI":"10.1016\/0959-8049(95)00053-L"},{"key":"R35-0558","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-911X(199804)30:4<228::AID-MPO4>3.0.CO;2-I"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2000.18.24.4067","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T21:35:14Z","timestamp":1653514514000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2000.18.24.4067"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,12,15]]},"references-count":35,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2000,12,15]]}},"alternative-id":["10.1200\/JCO.2000.18.24.4067"],"URL":"https:\/\/doi.org\/10.1200\/jco.2000.18.24.4067","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2000,12,15]]}}}